Secondary and exploratory analyses of the phase 3 NRG GY018 trial show that, in patients with advanced or recurrent endometrial cancer, first-line treatment with pembrolizumab together with paclitaxel and carboplatin leads to prolonged progression-free survival, according to blinded independent central review.
- Ramez N. Eskander
- Michael W. Sill
- Carol Aghajanian
